Literature DB >> 2548330

Modification of foot-and-mouth disease virus after serial passages in the presence of antiviral polyclonal sera.

E C Carrillo1, E R Rojas, L Cavallaro, M Schiappacassi, R Campos.   

Abstract

Foot-and-mouth disease virus (FMDV) shows a remarkable antigenic variability. Like other RNA viruses, this virus has a high rate of mutation. It has been proposed that selection exerted by the host's antibodies could play a major role in the rapid evolution of FMDV. The present work reports the selection of FMDV antibody-resistant populations (Nr), after serial passages of cloned FMDV A24 Cruzeiro strain on secondary monolayers of bovine fetal kidney cells in the presence of subneutralizing antiviral polyclonal sera (APS). After a limited number of passages under selective pressure, the virus population showed the following characteristics: (1) increased resistance to neutralization by APS; (2) altered electrophoretic mobility of structural viral proteins (VP1); (3) remarkable plaque size reduction, (4) a pronounced thermosensitivity (ts); and (5) decreased pathogenicity for mice, in both uncloned and cloned small plaque size populations. This indicates that FMDV populations under antibody pressure in vitro, have acquired, in addition to expected characteristics of natural FMDV variants (resistance to neutralization and altered viral structural proteins), phenotypic markers which correspond to attenuated, less virulent variants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548330     DOI: 10.1016/0042-6822(89)90629-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

1.  Distinct repertoire of antigenic variants of foot-and-mouth disease virus in the presence or absence of immune selection.

Authors:  B Borrego; I S Novella; E Giralt; D Andreu; E Domingo
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

2.  Modification of foot-and-mouth disease virus O1 Caseros after serial passages in the presence of antiviral polyclonal sera.

Authors:  E R Rojas; E Carrillo; M Schiappacassi; R Campos
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.